Boosting antibody developability through rational sequence optimization.


Abstract

The application of monoclonal antibodies as commercial therapeutics poses substantial demands on stability and properties of an antibody. Therapeutic molecules that exhibit favorable properties increase the success rate in development. However, it is not yet fully understood how the protein sequences of an antibody translates into favorable in vitro molecule properties. In this work, computational design strategies based on heuristic sequence analysis were used to systematically modify an antibody that exhibited a tendency to precipitation in vitro. The resulting series of closely related antibodies showed improved stability as assessed by biophysical methods and long-term stability experiments. As a notable observation, expression levels also improved in comparison with the wild-type candidate. The methods employed to optimize the protein sequences, as well as the biophysical data used to determine the effect on stability under conditions commonly used in the formulation of therapeutic proteins, are described. Together, the experimental and computational data led to consistent conclusions regarding the effect of the introduced mutations. Our approach exemplifies how computational methods can be used to guide antibody optimization for increased stability.

Submission Details

ID: oRPNZUHY

Submitter: Marie Ary

Submission Date: Nov. 29, 2018, 5:01 p.m.

Version: 1

Publication Details
Seeliger D;Schulz P;Litzenburger T;Spitz J;Hoerer S;Blech M;Enenkel B;Studts JM;Garidel P;Karow AR,MAbs (2015) Boosting antibody developability through rational sequence optimization. PMID:25759214
Additional Information

Structure view and single mutant data analysis

Study data

No weblogo for data of varying length.
Colors: D E R H K S T N Q A V I L M F Y W C G P
 

Data Distribution

Studies with similar sequences (approximate matches)

Correlation with other assays (exact sequence matches)


Relevant PDB Entries

Structure ID Release Date Resolution Structure Title
2RCJ 2008-01-22 Solution structure of human Immunoglobulin M
4LLD 2014-01-29 1.19 Structure of wild-type IgG1 antibody heavy chain constant domain 1 and light chain lambda constant domain (IgG1 CH1:Clambda) at 1.19A
3TV3 2011-10-19 1.29 Crystal structure of broad and potent HIV-1 neutralizing antibody PGT128 in complex with Man9
1YPQ 2005-02-08 1.4 Human Oxidized Low Density Lipoprotein Receptor LOX-1 Dioxane Complex
4LLQ 2014-01-29 1.42 Structure of redesigned IgG1 first constant and lambda domains (CH1:Clambda constant redesign 2 beta, CRD2b) at 1.42A
5HSF 2016-02-03 1.52 1.52 Angstrom Crystal Structure of Fc fragment of Human IgG1.
4NWU 2014-10-22 1.6 Crystal structure of APE1551, an anti-human NGF Fab with a nine amino acid insertion in CDR H1
5EWI 2016-11-23 1.6 Crystal Structure of the Human Fab VRC38.01, an HIV-1 V1V2-Directed Neutralizing Antibody Isolated from Donor N90
1L6X 2002-04-10 1.65 FC FRAGMENT OF RITUXIMAB BOUND TO A MINIMIZED VERSION OF THE B-DOMAIN FROM PROTEIN A CALLED Z34C
3TWC 2011-10-19 1.65 Crystal structure of broad and potent HIV-1 neutralizing antibody PGT127 in complex with Man9
5JIH 2017-04-12 1.66 Crystal structure of HER2 binding IgG1-Fc (Fcab STAB19)
5U66 2017-05-24 1.7 Modified single helix from the B-domain of protein A bound to IgG1 Fc
3MCL 2010-11-24 1.7 Anti-beta-amyloid antibody c706 fab in space group P21
6ARP 2018-08-29 1.7 Structure of a mutant Cetuximab Fab fragment
4BSV 2013-08-21 1.75 Heterodimeric Fc Antibody Azymetric Variant 1
4NWT 2014-10-22 1.75 Crystal structure of the anti-human NGF Fab APE1531
6N35 2018-11-28 1.75 Anti-HIV-1 Fab 2G12 + Man1-2 re-refinement
3DJ9 2008-09-16 1.75 Crystal Structure of an isolated, unglycosylated antibody CH2 domain
4LLM 2014-01-29 1.75 Structure of redesigned IgG1 first constant and lambda domains (CH1:Clambda constant redesign 1, CRD1) at 1.75A
4XMP 2015-04-29 1.78 Crystal structure of broadly and potently neutralizing antibody VRC08 in complex with HIV-1 clade A strain Q842.d12 gp120
1YXJ 2005-06-14 1.78 Crystal structure of human lectin-like oxidized low-density lipoprotein receptor 1 (LOX-1) at low pH
5JII 2017-04-12 1.79 Crystal structure of human IgG1-Fc
4W4O 2015-04-29 1.8 High-resolution crystal structure of Fc bound to its human receptor Fc-gamma-RI
3X12 2014-12-24 1.8 Crystal structure of HLA-B*57:01.I80N
1N0X 2004-04-13 1.8 Crystal Structure of a Broadly Neutralizing Anti-HIV-1 Antibody in Complex with a Peptide Mimotope
1N7M 2003-02-04 1.8 Germline 7G12 with N-methylmesoporphyrin
4W4N 2015-04-29 1.8 Crystal structure of human Fc at 1.80 A
3VH8 2011-10-26 1.8 KIR3DL1 in complex with HLA-B*5701
4B53 2012-12-05 1.8 Crystal structure of the isolated IgG4 CH3 domain
5HYF 2017-02-01 1.8 Glycosylated Knob-Knob Fc fragment (P6122)
5JIK 2017-04-12 1.82 Crystal structure of HER2 binding IgG1-Fc (Fcab H10-03-6)
1AQK 1998-02-04 1.84 THREE-DIMENSIONAL STRUCTURE OF A HUMAN FAB WITH HIGH AFFINITY FOR TETANUS TOXOID
5W5N 2017-09-13 1.85 Crystal structure of human IgG4-Sigma2 Fc fragment
4O4Y 2014-03-26 1.85 Crystal structure of the anti-hinge rabbit antibody 2095-2 in complex with IDES hinge peptide
5GSQ 2017-06-28 1.85 Crystal structure of IgG Fc with a homogeneous glycoform and Antibody-Dependent Cellular Cytotoxicity
6G1E 2019-04-10 1.88 BEAT Fc with improved heterodimerization (Q3A-D84.4Q)
5HYE 2017-02-01 1.89 Glycosylated Knob-Knob Fc fragment (P212121)
5DI8 2016-03-30 1.9 Fc Knob-Hole Heterodimer T366W + T366S/L368A/Y407V
3D85 2008-09-02 1.9 Crystal structure of IL-23 in complex with neutralizing FAB
4J12 2013-05-01 1.9 monomeric Fc
5W5L 2017-09-13 1.9 Crystal structure of human IgG1-Sigma Fc fragment
4WI7 2015-09-30 1.9 Structural mapping of the human IgG1 binding site for FcRn: hu3S193 Fc mutation H435A
6DCV 2018-06-06 1.9 Crystal structure of human anti-tau antibody CBTAU-27.1
4KU1 2014-02-19 1.9 Role of the hinge and C-gamma-2/C-gamma-3 interface in immunoglobin G1 Fc domain motions: implications for Fc engineering
5DJZ 2016-03-30 1.9 Fc Heterodimer Design 7.8 D399M/Y407A + T366V/K409V
4C54 2013-11-13 1.9 Crystal structure of recombinant human IgG4 Fc
5W5M 2017-09-13 1.9 Crystal structure of human IgG4-Sigma1 Fc fragment
5DVL 2016-03-30 1.9 Fc Design 20.8.37 A chain homodimer Y349S/T366M/K370Y/K409V
4WI2 2015-09-30 1.9 Structural mapping of the human IgG1 binding site for FcRn: hu3S193 Fc (wild-type)
4DZ8 2012-08-01 1.91 human IgG1 Fc fragment Heterodimer
4L4J 2013-08-28 1.92 Crystal structure of fc-fragment of human IgG2-Sigma antibody
5U52 2017-05-24 1.94 2 helix minimized version of the B-domain from Protein A (Z34C0 bound to IgG1 Fc (monoclinic form)
1GAF 1996-07-11 1.95 48G7 HYBRIDOMA LINE FAB COMPLEXED WITH HAPTEN 5-(PARA-NITROPHENYL PHOSPHONATE)-PENTANOIC ACID
4BM7 2013-07-03 1.95 Crystal Structure of IgG Fc F241A mutant with native glycosylation
5HVW 2016-08-17 1.95 Monomeric IgG4 Fc
4EOW 2012-08-22 1.97 Crystal structure of a disease-associated anti-human GM-CSF autoantibody MB007
5M3V 2017-05-10 1.97 BEAT Fc
3QCU 2011-03-30 1.98 Crystal structure of the LT3015 antibody Fab fragment in complex with lysophosphatidic acid (14:0)
6FCZ 2018-02-28 10.0 Model of gC1q-Fc complex based on 7A EM map
6DCW 2018-06-06 2.0 Crystal structure of human anti-tau antibody CBTAU-27.1 Fab in complex with a human tau peptide
6MSY 2018-11-21 2.0 Anti-HIV-1 Fab Fab 2G12 + Man4 re-refinement
1D5I 2000-02-09 2.0 UNLIGANDED GERMLINE PRECURSOR OF AN OXY-COPE CATALYTIC ANTIBODY
1VGE 1996-06-10 2.0 TR1.9 FAB FRAGMENT OF A HUMAN IGG1 KAPPA AUTOANTIBODY
5DJ6 2016-03-30 2.0 Fc Heterodimer Design 6.1 F405W/Y407A + T366M
1D6V 2000-02-09 2.0 CONFORMATION EFFECTS IN BIOLOGICAL CATALYSIS INTRODUCED BY OXY-COPE ANTIBODY MATURATION
3AVE 2011-04-06 2.0 Crystal Structure of the Fucosylated Fc Fragment from Human Immunoglobulin G1
3U0W 2012-10-03 2.0 AD related murine antibody Fragment
3WUW 2014-05-28 2.0 KIR3DL1 in complex with HLA-B*57:01.I80T
3V7M 2012-02-22 2.02 Crystal structure of monoclonal human anti-Rhesus D Fc IgG1 T125(YB2/0) in the presence of Zn2+
4HAF 2013-06-12 2.04 Crystal structure of fc-fragment of human IgG2 antibody (primitive crystal form)
1YPU 2005-02-08 2.05 Human Oxidized Low Density Lipoprotein Receptor LOX-1 C2 Space Group
5IW3 2017-03-29 2.05 anti-CD20 monoclonal antibody Fc fragment
3RU8 2011-11-02 2.07 Structure of an HIV epitope scaffold in complex with neutralizing antibody b12 Fab
5DJC 2016-03-30 2.1 Fc Heterodimer Design 8.1 L368V/Y407A + T366V/K409F
1A4J 1998-05-13 2.1 DIELS ALDER CATALYTIC ANTIBODY GERMLINE PRECURSOR
2RCS 1997-11-12 2.1 IMMUNOGLOBULIN 48G7 GERMLINE FAB-AFFINITY MATURATION OF AN ESTEROLYTIC ANTIBODY
1AJ7 1997-11-12 2.1 IMMUNOGLOBULIN 48G7 GERMLINE FAB ANTIBODY COMPLEXED WITH HAPTEN 5-(PARA-NITROPHENYL PHOSPHONATE)-PENTANOIC ACID. AFFINITY MATURATION OF AN ESTEROLYTIC ANTIBODY
4NQT 2014-03-12 2.1 anti-parallel Fc-hole(T366S/L368A/Y407V) homodimer
3AGV 2010-11-10 2.15 Crystal structure of a human IgG-aptamer complex
5O4E 2017-08-30 2.15 Crystal structure of VEGF in complex with heterodimeric Fcab JanusCT6
3X11 2014-12-24 2.15 Crystal structure of HLA-B*57:01.I80N.L82R.R83G
5DJY 2016-03-30 2.15 Fc Heterodimer Design 20.8 Y349S/T366V/K370Y/K409V + E357D/S364Q/Y407A
3QCT 2011-03-30 2.15 Crystal structure of the humanized apo LT3015 anti-lysophosphatidic acid antibody Fab fragment
4BSW 2013-08-21 2.15 Heterodimeric Fc Antibody Azymetric Variant 2
4Q74 2014-07-23 2.19 F241A Fc
2DTS 2007-03-13 2.2 Crystal Structure of the Defucosylated Fc Fragment from Human Immunoglobulin G1
4O51 2014-03-26 2.2 Crystal structure of the QAA variant of anti-hinge rabbit antibody 2095-2 in complex with IDES hinge peptide
3SGJ 2011-08-03 2.2 Unique carbohydrate-carbohydrate interactions are required for high affinity binding between FcgIII and antibodies lacking core fucose
3AY4 2011-08-03 2.2 Crystal structure of nonfucosylated Fc complexed with bis-glycosylated soluble form of Fc gamma receptor IIIa
6N32 2018-11-28 2.2 Anti-HIV-1 Fab 2G12 re-refinement
4WI6 2015-09-30 2.2 Structural mapping of the human IgG1 binding site for FcRn: hu3S193 Fc mutation N434A
4HIX 2013-03-13 2.2 Crystal structure of a humanised 3D6 Fab bound to amyloid beta peptide
5DJX 2016-03-30 2.25 Fc Heterodimer Design 2.9 L368M/K370E + E357A/S364G
5VU0 2018-05-23 2.26 Crystal structure of the complex between afucosylated/galactosylated human IgG1 Fc and Fc gamma receptor IIIa (CD16A) with Man5 N-glycans
5DJ0 2016-03-30 2.28 Fc Heterodimer Design 11.2 Y349S/K370Y + E357D/S364Q
6F2Z 2018-12-12 2.3 Structure of a Fc mutatnt
3VLG 2012-04-18 2.3 Crystal structure of the W150A mutant LOX-1 CTLD showing impaired OxLDL binding
4BYH 2013-08-21 2.3 Crystal structure of sialylated IgG Fc
1OQO 2003-03-20 2.3 Complex between G0 version of an Fc bound to a minimized version of Protein A called Mini-Z
5DK0 2016-03-30 2.3 Fc Heterodimer Design 20.8.34 Y349S/T366M/K370Y/K409V + E356G/E357D/S364Q/Y407A
2NY7 2007-02-06 2.3 HIV-1 gp120 Envelope Glycoprotein Complexed with the Broadly Neutralizing CD4-Binding-Site Antibody b12
3C2S 2008-08-19 2.3 Structural Characterization of a Human Fc Fragment Engineered for Lack of Effector Functions
5DJD 2016-03-30 2.3 Fc Heterodimer Design 5.1 T366V + Y407F
5B38 2016-03-30 2.3 KIR3DL1*005 in complex with HLA-B*57:01
4XNY 2015-04-29 2.3 Crystal structure of broadly and potently neutralizing antibody VRC08C in complex with HIV-1 clade A strain Q842.d12 gp120
4CDH 2014-11-12 2.3 Crystallographic structure of the Human Igg1 alpha 2-6 sialilated Fc-Fragment
1I7Z 2001-08-08 2.3 ANTIBODY GNC92H2 BOUND TO LIGAND
3D6G 2009-06-16 2.3 Fc fragment of IgG1 (Herceptin) with protein-A mimetic peptide dendrimer ligand.
5V43 2017-06-21 2.32 Engineered human IgG Fc domain aglyco801
6MU3 2018-10-31 2.33 Anti-HIV-1 Fab 2G12 + Man7 re-refinement
5IW6 2017-03-29 2.34 anti-CD20 monoclonal antibody Fc fragment
2IWG 2007-03-27 2.35 COMPLEX BETWEEN THE PRYSPRY DOMAIN OF TRIM21 AND IGG FC
4Q7D 2014-07-23 2.35 Wild type Fc (wtFc)
4C55 2013-11-13 2.35 Crystal structure of serum-derived human IgG4 Fc
4B7I 2012-10-17 2.36 Crystal Structure of Human IgG Fc Bearing Hybrid-type Glycans
5D4Q 2016-02-10 2.39 Crystal structure of GASDALIE IgG1 Fc
1A4K 1998-05-13 2.4 DIELS ALDER CATALYTIC ANTIBODY WITH TRANSITION STATE ANALOGUE
5DJ8 2016-03-30 2.4 Fc Heterodimer Design 7.7 D399M/Y407A + T366V/K409I
5XJE 2017-11-01 2.4 Crystal structure of fucosylated IgG1 Fc complexed with bis-glycosylated soluble form of Fc gamma receptor IIIa
1H3T 2003-01-23 2.4 Crystal structure of the human igg1 fc-fragment,glycoform (mn2f)2
1H3U 2003-01-23 2.4 CRYSTAL STRUCTURE OF THE HUMAN IGG1 FC-FRAGMENT,GLYCOFORM (M3N2F)2
1YXK 2005-06-14 2.4 Crystal structure of human lectin-like oxidized low-density lipoprotein receptor 1 (LOX-1) disulfide-linked dimer
6BZ4 2018-06-13 2.4 Human IgG1 lacking complement-dependent cytotoxicity: hu3S193 Fc mutant K322A
3SGK 2011-08-03 2.4 Unique carbohydrate/carbohydrate interactions are required for high affinity binding of FcgIII and antibodies lacking core fucose
4XXD 2015-04-29 2.41 Crystal Structure of mid-region amyloid beta capture by solanezumab
4ZNE 2015-11-11 2.42 IgG1 Fc-FcgammaRI ecd complex
5K64 2017-09-06 2.44 Crystal structure of VEGF binding IgG1-Fc (Fcab 448)
1H3X 2003-11-20 2.44 CRYSTAL STRUCTURE OF THE HUMAN IGG1 FC-FRAGMENT,GLYCOFORM (G0F)2
6AYN 2017-12-13 2.48 Structure of cetuximab with aminoheptanoic acid-linked N-(3-aminopropyl)-L-arginine meditope variant
6AXP 2017-12-13 2.48 Structure of cetuximab with aminoheptanoic acid-linked n-octylarginine meditope variant
6AZK 2017-12-13 2.48 Structure of cetuximab with aminoheptanoic acid-linked N-(3-hydroxypropyl)-L-arginine meditope variant
6AZL 2017-12-13 2.48 Structure of cetuximab with aminoheptanoic acid-linked N-carboxyethylarginine meditope variant
6AU5 2017-12-13 2.48 Structure of cetuximab with aminoheptanoic acid-linked n-butylarginine meditope variant
4ACP 2012-04-25 2.49 Deactivation of human IgG1 Fc by endoglycosidase treatment
1CLY 1996-08-01 2.5 IGG FAB (HUMAN IGG1, KAPPA) CHIMERIC FRAGMENT (CBR96) COMPLEXED WITH LEWIS Y NONOATE METHYL ESTER
5VZX 2017-08-09 2.5 Crystal structure of crenezumab Fab
3FJT 2009-03-24 2.5 Crystal structure of a human Fc fragment engineered for extended serum half-life
4NQU 2014-03-12 2.5 anti-parallel Fc-knob (T366W) homodimer
5U4Y 2017-05-17 2.5 IgG Fc bound to 3 helix of the B-domain from Protein A
1UCB 1997-03-12 2.5 STRUCTURE OF UNCOMPLEXED FAB COMPARED TO COMPLEX (1CLY, 1CLZ)
2RFX 2008-07-08 2.5 Crystal Structure of HLA-B*5701, presenting the self peptide, LSSPVTKSF
5XJF 2017-11-01 2.5 Crystal structure of fucosylated IgG Fc Y296W mutant complexed with bis-glycosylated soluble form of Fc gamma receptor IIIa
4R26 2014-10-08 2.5 Crystal structure of human Fab PGT124, a broadly neutralizing and potent HIV-1 neutralizing antibody
5DVO 2016-03-30 2.5 Fc K392D/K409D homodimer
1PG7 2003-08-26 2.5 Murine 6A6 Fab in complex with humanized anti-Tissue Factor D3H44 Fab
5K65 2017-09-06 2.5 Crystal structure of VEGF binding IgG1-Fc (Fcab CT6)
6FGO 2018-06-20 2.5 Fc in complex with engineered calcium binding domain Z
4X99 2015-06-03 2.5 Immunoglobulin Fc heterodimers variant
3DO3 2009-07-21 2.5 Human 1gG1 Fc fragment, 2.5 Angstrom structure
6MUB 2018-10-31 2.5 Anti-HIV-1 Fab 2G12 + Man5 re-refinement
5DVN 2016-03-30 2.5 Fc K392D/K409D homodimer
4X98 2015-06-03 2.5 Immunoglobulin Fc heterodimer variant
5B39 2016-03-30 2.5 KIR3DL1*015 in complex with HLA-B*57:01
2WAH 2009-03-10 2.51 Crystal Structure of an IgG1 Fc Glycoform (Man9GlcNAc2)
3QCV 2011-03-30 2.51 Crystal structure of the LT3015 antibody Fab fragment in complex with lysophosphatidic acid (18:2)
2QL1 2008-04-01 2.53 Structural Characterization of a Mutated, ADCC-Enhanced Human Fc Fragment
5DJ2 2016-03-30 2.56 Fc Heterodimer Design 7.4 Y407A + T366V/K409V
1MIM 1997-05-15 2.6 IGG FAB FRAGMENT (CD25-BINDING)
3WJJ 2013-11-13 2.6 Crystal structure of IIb selective Fc variant, Fc(P238D), in complex with FcgRIIb
5DVK 2016-03-30 2.6 Fc Design 7.7 B chain homodimer T366V/K409I
3U7W 2011-11-16 2.6 Crystal structure of NIH45-46 Fab
5DK2 2016-03-30 2.6 Fc Heterodimer E356K/D399K + K392D/K409D
1AXS 1998-02-04 2.6 MATURE OXY-COPE CATALYTIC ANTIBODY WITH HAPTEN
5WAV 2017-11-08 2.6 Fc AbVance: Increasing our knowledge of antibody structural space to enable faster and better decision-making in antibody drug discovery.
1OQX 2003-03-25 2.6 G-2 glycovariant of human IgG Fc bound to minimized version of Protein A called Z34C
4D3C 2016-01-13 2.62 Crystal structure of the NK1 domain of HGF in complex with anti-HGF monoclonal antibody SFN68.
4NQS 2014-03-12 2.64 Knob-into-hole IgG Fc
4WI9 2015-09-30 2.65 Structural mapping of the human IgG1 binding site for FcRn: hu3S193 Fc mutation I253A/H310A
4NM4 2013-12-25 2.65 Crystal structure of broadly neutralizing antibody CR8043
5Y56 2017-09-13 2.65 Fc mutant (K392D/K409D/D399K)
1HKL 1997-03-12 2.68 FREE AND LIGANDED FORM OF AN ESTEROLYTIC CATALYTIC ANTIBODY
1HZH 2001-08-15 2.7 CRYSTAL STRUCTURE OF THE INTACT HUMAN IGG B12 WITH BROAD AND POTENT ACTIVITY AGAINST PRIMARY HIV-1 ISOLATES: A TEMPLATE FOR HIV VACCINE DESIGN
1HEZ 2001-08-10 2.7 antibody-antigen complex
4WI3 2015-09-30 2.7 Structural mapping of the human IgG1 binding site for FcRn: hu3S193 Fc mutation I253A
5LG1 2016-12-14 2.7 Room temperature structure of human IgG4-Fc from crystals analysed in situ
1DN2 2000-05-17 2.7 FC FRAGMENT OF HUMAN IGG1 IN COMPLEX WITH AN ENGINEERED 13 RESIDUE PEPTIDE DCAWHLGELVWCT-NH2
4D2N 2014-07-02 2.7 Crystal structure of deglycosylated serum-derived human IgG4 Fc
3V95 2012-02-22 2.7 Crystal structure of monoclonal human anti-rhesus D Fc and IgG1 t125(yb2/0) in the presence of EDTA
1DFB 1993-10-31 2.7 STRUCTURE OF A HUMAN MONOCLONAL ANTIBODY FAB FRAGMENT AGAINST GP41 OF HUMAN IMMUNODEFICIENCY VIRUS TYPE I
5HY9 2017-02-01 2.7 Glycosylated, disulfide-linked Knob-into-Hole Fc fragment
4YDV 2015-08-12 2.7 STRUCTURE OF THE ANTIBODY 7B2 THAT CAPTURES HIV-1 VIRIONS
5TPS 2017-10-25 2.7 Structure of a Fc heterodimer
5YC5 2018-03-21 2.71 Crystal structure of human IgG-Fc in complex with aglycan and optimized Fc gamma receptor IIIa
3V8C 2012-02-22 2.77 Crystal structure of monoclonal human anti-rhesus D Fc IgG1 t125(yb2/0) double mutant (H310 and H435 in K)
3WN5 2014-11-19 2.78 Crystal structure of asymmetrically engineered Fc variant in complex with FcgRIIIa
1FC2 1981-10-02 2.8 Crystallographic Refinement and Atomic Models of a Human FC Fragment and its Complex with Fragment B of Protein A from Staphylococcus Aureus at 2.9-and 2.8-Angstroms Resolution
3O11 2010-09-08 2.8 Anti-beta-amyloid antibody c706 fab in space group c2
5XMH 2018-03-21 2.8 Crystal structure of an IgM rheumatoid factor YES8c in complex with IgG1 Fc
1D5B 2000-02-09 2.8 UNLIGANDED MATURE OXY-COPE CATALYTIC ANTIBODY
4WI8 2015-09-30 2.8 Structural mapping of the human IgG1 binding site for FcRn: hu3S193 Fc mutation Y436A
4WI4 2015-09-30 2.8 Structural mapping of the human IgG1 binding site for FcRn: hu3S193 Fc mutation S254A
4WI5 2015-09-30 2.8 Structural mapping of the human IgG1 binding site for FcRn: hu3S193 Fc mutation H310A
3DNK 2009-07-21 2.84 Enzyme deglycosylated Human IgG1 Fc fragment
1H3W 2003-01-23 2.85 Structural analysis of human IgG-Fc glycoforms reveals a correlation between glycosylation and structural integrity
3WJL 2013-11-13 2.86 Crystal structure of IIb selective Fc variant, Fc(V12), in complex with FcgRIIb
3IU3 2010-01-26 2.9 Crystal structure of the Fab fragment of therapeutic antibody Basiliximab in complex with IL-2Ra (CD25) ectodomain
5DJA 2016-03-30 2.9 Fc Heterodimer Design 9.1 Y407M + T366I
1FC1 1981-10-02 2.9 CRYSTALLOGRAPHIC REFINEMENT AND ATOMIC MODELS OF A HUMAN FC FRAGMENT AND ITS COMPLEX WITH FRAGMENT B OF PROTEIN A FROM STAPHYLOCOCCUS AUREUS AT 2.9-AND 2.8-ANGSTROMS RESOLUTION
5HYI 2017-02-01 2.9 Glycosylated, disulfide-linked Hole-Hole Fc fragment
3WKN 2014-10-29 2.9 Crystal structure of the artificial protein AFFinger p17 (AF.p17) complexed with Fc fragment of human IgG
5DVM 2016-03-30 2.95 Fc Design 20.8.37 B chain homodimer E357D/S364R/Y407A
4Q6Y 2014-07-23 3.0 Crystal structure of a chemoenzymatic glycoengineered disialylated Fc (di-sFc)
2J6E 2007-04-10 3.0 Crystal Structure of an Autoimmune Complex between a Human IgM Rheumatoid Factor and IgG1 Fc reveals a Novel Fc Epitope and Evidence for Affinity Maturation
1YPO 2005-02-08 3.0 Human Oxidized Low Density Lipoprotein Receptor LOX-1 P3 1 21 Space Group
1T83 2004-09-28 3.0 CRYSTAL STRUCTURE OF A HUMAN TYPE III FC GAMMA RECEPTOR IN COMPLEX WITH AN FC FRAGMENT OF IGG1 (ORTHORHOMBIC)
6IQG 2019-02-13 3.0 X-ray crystal structure of Fc and peptide complex
5BW7 2015-10-14 3.0 Crystal structure of nonfucosylated Fc Y296W mutant complexed with bis-glycosylated soluble form of Fc gamma receptor IIIa
6N2X 2018-11-28 3.0 Anti-HIV-1 Fab 2G12 + Man9 re-refinement
6IQH 2019-02-13 3.0 X-ray crystal structure of covalent-bonded complex of Fc and peptide
3EO1 2008-12-02 3.1 Structure of the Fab Fragment of GC-1008 in Complex with Transforming Growth Factor-Beta 3
1H3V 2003-01-23 3.1 CRYSTAL STRUCTURE OF THE HUMAN IGG1 FC-FRAGMENT,GLYCOFORM (G2F)2,SG P212121
1BBJ 1994-01-31 3.1 CRYSTAL STRUCTURE OF A CHIMERIC FAB' FRAGMENT OF AN ANTIBODY BINDING TUMOUR CELLS
3S7G 2012-05-30 3.13 Aglycosylated human igg1 fc fragment
5D6D 2016-02-10 3.13 Crystal structure of GASDALIE IgG1 Fc in complex with FcgRIIIa
1ADQ 1998-09-16 3.15 CRYSTAL STRUCTURE OF A HUMAN IGM RHEUMATOID FACTOR FAB IN COMPLEX WITH ITS AUTOANTIGEN IGG FC
6OKQ 2019-06-05 3.2 Crystal structure of the SF12 Fab
1E4K 2000-08-06 3.2 CRYSTAL STRUCTURE OF SOLUBLE HUMAN IGG1 FC FRAGMENT-FC-GAMMA RECEPTOR III COMPLEX
1FCC 1995-04-20 3.2 CRYSTAL STRUCTURE OF THE C2 FRAGMENT OF STREPTOCOCCAL PROTEIN G IN COMPLEX WITH THE FC DOMAIN OF HUMAN IGG
5V4E 2017-06-21 3.22 Engineered human IgG Fc domain glyco801 (Fc801)
3TYG 2011-10-19 3.25 Crystal structure of broad and potent HIV-1 neutralizing antibody PGT128 in complex with a glycosylated engineered gp120 outer domain with miniV3 (eODmV3)
5K33 2017-04-12 3.3 Crystal structure of extracellular domain of HER2 in complex with Fcab STAB19
4XNZ 2015-04-29 3.39 Crystal structure of broadly and potently neutralizing antibody VRC06B in complex with HIV-1 clade A/E strain 93TH057 gp120
4HAG 2013-06-12 3.4 Crystal structure of fc-fragment of human IgG2 antibody (centered crystal form)
4X4M 2015-04-08 3.48 Structure of FcgammaRI in complex with Fc reveals the importance of glycan recognition for high affinity IgG binding
1T89 2004-09-14 3.5 CRYSTAL STRUCTURE OF A HUMAN TYPE III FC GAMMA RECEPTOR IN COMPLEX WITH AN FC FRAGMENT OF IGG1 (HEXAGONAL)
3RY6 2011-08-31 3.8 Complex of fcgammariia (CD32) and the FC of human IGG1
4N0U 2014-02-05 3.8 Ternary complex between Neonatal Fc receptor, serum albumin and Fc
5W1K 2018-05-30 3.99 JUNV GP1 CR1-10 Fab CR1-28 Fab complex
4NM8 2013-12-25 4.0 Crystal structure of broadly neutralizing antibody CR8043 bound to H3 influenza hemagglutinin
1H3Y 2003-01-23 4.1 Crystal structure of a human IgG1 Fc-fragment,high salt condition
6DE7 2018-06-06 4.12 Crystal Structure at 4.3 A Resolution of Glycosylated HIV-1 Clade A BG505 SOSIP.664 Prefusion Env Trimer with Interdomain Stabilization 113C-429GCG in Complex with Broadly Neutralizing Antibodies PGT122 and 35O22
5K8D 2017-06-14 4.19 Crystal structure of rFVIIIFc
5KWG 2017-04-12 4.3 Crystal structure of extracellular domain of HER2 in complex with Fcab H10-03-6
2GJ7 2006-05-30 5.0 Crystal Structure of a gE-gI/Fc complex

Relevant UniProtKB Entries

Percent Identity Matching Chains Protein Accession Entry Name
99.1 CL Anti-LOX-1 (lectin-type optimized LDL receptor 1) mAb1 P0DOX7 IGK_HUMAN
99.1 CL Anti-LOX-1 (lectin-type optimized LDL receptor 1) mAb1 P01834 IGKC_HUMAN
91.5 CH Anti-LOX-1 (lectin-type optimized LDL receptor 1) mAb1 P01861 IGHG4_HUMAN
91.5 CH Anti-LOX-1 (lectin-type optimized LDL receptor 1) mAb1 P01859 IGHG2_HUMAN
99.4 CH Anti-LOX-1 (lectin-type optimized LDL receptor 1) mAb1 P01857 IGHG1_HUMAN
99.4 CH Anti-LOX-1 (lectin-type optimized LDL receptor 1) mAb1 P0DOX5 IGG1_HUMAN
99.1 Oxidized low-density lipoprotein receptor 1 (LOX-1) P78380 OLR1_HUMAN